BMEA Biomea Fusion Inc
Company Analysis
Latest News
🟢 Biomea Fusion is trading 10.38% up today after completing COVALENT-211 enrollment
Biomea Fusion is trading 10.38% up at $1.75 after investors continued responding to the August 24 completion of enrollment in the COVALENT-211 Phase II...
🟢 Biomea Fusion is trading 5% up today after completing Phase II trial enrollment
Biomea Fusion is trading 5.03% up at $1.67 after investors continued responding to the August 24 completion of enrollment in the COVALENT-211 Phase II...
Biomea Fusion Hits a Trial Milestone, but Can a $1.68 Stock Survive Long Enough to Prove Its Diabetes Drug Works
Shares of Biomea Fusion surged 22.3% to $1.68 after the micro-cap biotech announced it finished enrolling patients in a key mid-stage trial of its experimental...
🟢 Biomea Fusion is trading 23% up today after completing Phase II COVALENT-211 enrollment
Biomea Fusion is trading $1.68 (+22.68%) following its August 24, 2026 announcement that enrollment was complete in the randomized Phase II COVALENT-211 trial...
🟢 Biomea Fusion is trading 8% up in pre-market with no confirmed company-specific catalyst identified
Biomea Fusion is trading 8.03% up at $1.48, with no confirmed company-specific catalyst identified. - The stock rose from the August 21 close of $1.37. - No...
Biomea Fusion begins obesity trial, combining icovamenib with semaglutide for muscle health
Biomea Fusion dosed the first participant in a new arm of its OPAL research study. This trial evaluates the investigational drug icovamenib in combination with...
Citi Places Biomea Fusion on "Upside 90-Day Catalyst Watch"
On August 11, 2026, a Citi analyst identified Biomea Fusion Inc. as a stock to watch for positive developments over the next 90 days, maintaining a Buy rating...
Biomea Fusion reports a narrowed second quarter net loss of $0.12 per share, citing reduced operating expenses.
Biomea Fusion, a clinical-stage company, reported a significantly narrowed net loss for the second quarter, driven by lower research and development and...
Biomea Fusion Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
For the second quarter of 2026, Biomea Fusion is expected to report a loss per share of $0.21 on zero revenue, with the current stock price of $1.17 trading...